Bradykinin receptor ligands: Therapeutic perspectives

Nature Reviews Drug Discovery

Volumn 3, Issue 10, 2004, Pages 845-852

  Marceau, François ^a   Regoli, Domenico ^b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; B 9430; B 9870; BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ RECEPTOR; BRADYKININ RECEPTOR AGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; G PROTEIN COUPLED RECEPTOR; ICATIBANT; KALLIKREIN; KININ; LIGAND; LOBRADIMIL; LYSYLLYSYLARGINYLPROLYL(4 HYDROXYPROLYL)GLYCYL 2 (2,3 DIHYDRO 1H INDEN 2 YL)GLYCYLSERYL 2 (2,3 DIHYDRO 1H INDEN 2 YL)GLYCYLOCTAHYDRO 1H INDOLE 2 CARBOXYLIC ACID; OMAPATRILAT; PEPTIDE; PLASMA PROTEIN; R 954; RAMIPRIL; RECEPTOR SUBTYPE; SSR 240612; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ANGIONEUROTIC EDEMA; CIRCULATION; CLINICAL TRIAL; COUGHING; DRUG ABUSE; DRUG INDICATION; DRUG INHIBITION; DRUG RESEARCH; DRUG STRUCTURE; DRUG TOLERANCE; ENZYME ACTIVITY; GENETICS; HUMAN; INFLAMMATION; KALLIKREIN KININ SYSTEM; KIDNEY FUNCTION; MOLECULAR BIOLOGY; NONHUMAN; PAIN; PATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW;

ANIMALS; HUMANS; INFLAMMATION MEDIATORS; KININS; LIGANDS; PAIN; PEPTIDES; RECEPTORS, BRADYKININ;

EID: 6444236841     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1522     Document Type: Review

References (65)

1. Blais, C. Jr, Marceau, F., Rouleau, J. L. & Adam, A. The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. Peptides 21, 1903-1940 (2000).
2. Linz, W., Wiemer, G., Gohlke, P., Unger, T. & Shoelkens, B. A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47, 25-49 (1995).
3. Gainer, J. V., Morrow, J. D., Loveland, A., King, D. J. & Brown, N. J. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N. Engl. J. Med. 339, 1285-1292 (1998).
4. 2 receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men. Hypertension 36, 132-136 (2000).
5. Regoli, D. & Barabé, J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32, 1-46 (1980).
6. 1 receptors for kinins. Pharmacol. Rev. 50, 357-386 (1998).
7. 2 bradykinin receptor. Proc. Natl Acad. Sci. USA 88, 7724-7728 (1991).
8. 1 bradykinin receptor. J. Biol. Chem. 269, 21583-21586 (1994 ).
9. 2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J. Biol. Chem. 270, 13706-13710 (1995).
10. 1 receptors. Proc. Natl Acad, Sci. USA 97, 8140-8145 (2000).
11. 2 receptors. Hypertension 29, 483-487 (1997).
12. Cayla, C. et al. Structure of the mammalian kinin receptor gene locus. Int. Immunopharmacol. 2, 1721-1727 (2002).
13. Dhamrait, S. S. et al. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur. Heart. J. 24, 1672-1680 (2003).
14. 2 receptor antagonists. J. Med. Chem. 45, 2160-2172 (2002).
15. 1 receptor antagonist, J. Am. Chem. Soc. 125, 7516-7517 (2003).
16. 1 receptor. Biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 309 661-669 (2004).
17. 1 receptor based on a 2-alkylamino-5-sulfamoylbenzamide core. J. Med. Chem. 47, 4642-4644(2004).
18. Emerich, D. F. et al. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation. Clin. Pharmacokinet. 40, 105-123 (2001).
19. 1 receptor for therapeutic neovascularization. Circulation 105, 360-366 (2002).
20. Schmaier, A. H. The physiologic basis of assembly and activation of the plasma kallikrein/kinin system. Thromb. Haemost. 91, 1-3 (2004).
21. Mahdi, F. et al. Mapping the interaction between high molecular weight kininogen and the urokinase plasminogen activator receptor. J. Biol. Chem. 279, 16621-16628 (2004).
22. Margolius, H. S. Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Clin. Rev. Allergy Immunol. 16, 337-349 (1998).
23. Stadnicki, A. et al. Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease. Dig. Dis. Sci. 48, 615-623 (2003).
24. Batenburg, W. W., Garrelds, I. M., van Kats, J. P., Saxena, P. R. & Danser, A. H. Mediators of bradykinin-induced vasorelaxation in human coronary microarteries. Hypertension 43, 488-492 (2004).
25. 1 receptors in allergic airway inflammation. J. Immunol. 169, 2054-2060 (2002).
26. 1 receptor up-regulation after lipopolysaccharide administration: role of proinflammatory cytokines and neutrophil influx. J. Immunol. 172, 1839-1847 (2004).
27. 1 receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J. Immunol. 172, 2542-2548 (2004).
28. Blaukat, A. et al. Overexpression and functional characterization of kinin receptors reveal subtype-specific phosphorylation. Biochemistry 38, 1300-1309 (1999).
29. 2 receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates. J. Pharmacol, Exp. Ther. 297, 19-26 (2001).
30. 1 receptor to caveolae-related rafts. Mol. Pharmacol. 61, 546-553 (2002).
31. Pretorius, M., Rosenbaum, D., Vaughan, D. E. & Brown, N. J. Angiotensin-converting enzyme inhibition increases human vascular-type plasminogen activator release through endogenous bradykinin. Circulation 107, 579-585 (2003).
32. 9-bradykinin. J. Pharmacol. Exp. Ther. 303, 232-237 (2002).
33. Sulpizio, A., Pullen, M. A., Edwards, R. M. & Brooks, D. P. The affect of acute angiotensin converting enzyme (ACE) and neutral endopeptidase 24.11 (NEP) inhibition on plasma extravasation in the rat. J. Pharmacol. Exp. Ther. 309, 1141-1147 (2004).
34. 2-receptor-dependent mechanism. Hypertension 41, 1092-1095 (2003).
35. 2 receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. Br. J. Pharmacol. 136, 484-491 (2002).
36. Aliberti, J. et al. Cutting edge: bradykinin induces IL-12 production by dendritic cells: a danger signal that drives Th1 polarization. J. Immunol. 170, 5349-5553 (2003).
37. 1 receptor antagonists containing α-methyl-l-phenylalanine: in vitro and in vivo antagonistic activities. Hypertension 33, 823-829 (1999).
38. 1 receptor antagonists with multienzymatic resistance properties. Can. J. Physiol. Pharmacol. 80, 287-292 (2002).
39. 1 receptors. Immunopharmacology 33, 183-185 (1996).
40. Vavrek, R. J. & Stewart, J. M. Competitive antagonists of bradykinin. Peptides 6, 161-164 (1985).
41. Stewart, J. M. Bradykinin antagonists: discovery and development. Peptides 25, 527-532 (2004).
42. Hock, F. J. et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol. 102, 769-773 (1991).
43. Chan, D. et al. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a « biased agonist » mechanism. Proc. Natl Acad. Sci. USA 99, 4608-4613.
44. 2 receptor antagonist, FR173657. Br. J. Pharmacol. 120, 617-624 (1997).
45. 2 receptor antagonist. Immunopharmacology 43, 187-194 (1999).
46. 2 receptor antagonist FR173657 in models of visceral and cutaneous inflammation. Inflamm. Res. 49, 535-540 (2000).
47. Uknis, A. B. et al. Bradykinin receptor antagonists type 2 attenuate the inflammatory changes in peptidoglycan-induced acute arthritis in the Lewis rat. Inflamm. Res. 50, 149-155 (2001).
48. 2 transgenic knockout mice. Br. J. Pharmacol. 129, 1732-1738 (2000).
49. 2 receptor antagonist, reduces brain edema and improves long-term neurological function recovery after closed head trauma in rats. J. Neurotrauma 19, 953-964 (2002).
50. 2 receptor antagonist, on brain edema formation and tissue damage in a rat model of temporary focal cerebral ischemia. Brain Res. 950, 268-278 (2002).
51. Narotam, P. K. et al. Traumatic brain contusions: a clinical role for the kinin antagonist CP-0127. Acta Neurochir. (Wien 140, 793-802 (1998).
52. Eric, J., Gabra, B. H. & Sirois, P. Implication of the bradykinin receptors in antigen-induced pulmonary inflammation in mice. Br. J. Pharmacol. 138, 1589-1597 (2003).
53. 2 receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br. J. Pharmacol. 129, 77-86 (2000).
54. 2 bradykinin receptors and antinociceptive effects of their antagonists in an animal model of neuropathic pain. Pain 86, 265-271 (2000).
55. 1 receptors in the spinal cord in humans and rats. Neuroreport 12 2311-2314 (2001).
56. 1 rerceptor is constitutively expressed in the rat sensory nervous system. Neurosci. Lett. 294, 175-178 (2000).
57. 2 receptors: normal distribution and alterations induced by epilepsy. J. Comp. Neurol. 461, 506-519 (2003).
58. 1 bradykinin receptor biological activity in two experimental models of epilepsy. Neuroscience 92, 1043-1049 (1999).
59. 1 transgenic rat as a pharmacodynamic model. J. Pharmacol. Exp. Ther. 310, 488-497 (2004).
60. Fein, A. M. et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 277, 482-487 (1997).
61. 1 receptors in diabetes-induced hyperalgesia in streptozotocin-treated mice. Eur. J. Pharmacol. 457, 115-124 (2002).
62. Zuccollo, A, et al. The involvement of kallikrein-kinin system in diabetes type I (insulitis). Immunopharmacology 45, 69-74 (1999).
63. Wang, C. H. et al. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker. Circulation 107, 1923-1929 (2003).
64. Shiuchi, T. et al. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 40, 329-334 (2002).
65. Izhar, M., Alausa, T., Folker, A., Hung, E. & Bakris, G. L. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension 43, 573-577 (2004).